Paradigm Biopharmaceuticals Ltd (PAR) - Cash Flow Conversion Efficiency

Latest as of December 2025: -3.276x

Based on the latest financial reports, Paradigm Biopharmaceuticals Ltd (PAR) has a cash flow conversion efficiency ratio of -3.276x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-19.65 Million ≈ $-13.90 Million USD) by net assets (AU$6.00 Million ≈ $4.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Paradigm Biopharmaceuticals Ltd (PAR) net asset quality to measure how much of total assets are equity-financed.

Paradigm Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Paradigm Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Paradigm Biopharmaceuticals Ltd (PAR) long-term investment share to see how much of total assets are deployed in long-term investments.

Paradigm Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Paradigm Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Happy City Holdings Limited Class A Ordinary shares NASDAQ:HCHL	N/A
2invest AG XETRA:2INV	N/A
Alterity Therapeutics Ltd NASDAQ:ATHE	-0.192x
THN Corporation KO:019180	-0.042x
Vakrangee Limited NSE:VAKRANGEE	0.093x
GrowGeneration Corp NASDAQ:GRWG	-0.005x
Huikwang TWO:6508	0.041x
Adicet Bio Inc NASDAQ:ACET	-0.153x

Annual Cash Flow Conversion Efficiency for Paradigm Biopharmaceuticals Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Paradigm Biopharmaceuticals Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Paradigm Biopharmaceuticals Ltd worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$21.18 Million ≈ $14.99 Million	AU$-15.99 Million ≈ $-11.32 Million	-0.755x	+72.75%
2024-06-30	AU$23.81 Million ≈ $16.84 Million	AU$-65.94 Million ≈ $-46.66 Million	-2.770x	-229.06%
2023-06-30	AU$53.68 Million ≈ $37.98 Million	AU$-45.19 Million ≈ $-31.97 Million	-0.842x	-10.60%
2022-06-30	AU$42.31 Million ≈ $29.94 Million	AU$-32.21 Million ≈ $-22.79 Million	-0.761x	-70.56%
2021-06-30	AU$78.27 Million ≈ $55.38 Million	AU$-34.93 Million ≈ $-24.71 Million	-0.446x	-378.45%
2020-06-30	AU$108.18 Million ≈ $76.55 Million	AU$-10.09 Million ≈ $-7.14 Million	-0.093x	-21.34%
2019-06-30	AU$82.81 Million ≈ $58.59 Million	AU$-6.37 Million ≈ $-4.50 Million	-0.077x	+82.28%
2018-06-30	AU$13.86 Million ≈ $9.81 Million	AU$-6.01 Million ≈ $-4.25 Million	-0.434x	-29.92%
2017-06-30	AU$13.39 Million ≈ $9.47 Million	AU$-4.47 Million ≈ $-3.16 Million	-0.334x	-4.51%
2016-06-30	AU$11.23 Million ≈ $7.95 Million	AU$-3.59 Million ≈ $-2.54 Million	-0.319x	-284.01%
2015-06-30	AU$14.46 Million ≈ $10.23 Million	AU$-1.20 Million ≈ $-851.40K	-0.083x	-102.05%
2014-06-30	AU$-151.87K ≈ $-107.45K	AU$-617.72K ≈ $-437.08K	4.068x	--

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology

Market Cap

$70.64 Million

AU$99.84 Million AUD

Market Cap Rank

#20563 Global

#684 in Australia

Share Price

AU$0.19

Change (1 day)

+8.57%

52-Week Range

AU$0.14 - AU$0.45

All Time High

AU$4.35